Research progress in immunotherapy and targeted therapy for gastric cancer and esophagogastric junction cancer

doi:10.3760/cma.j.cn371439-20240716-00099

Abstract

Abstract:

Gastric cancer and esophagogastric junction cancer （EGJC） are one of the world's most common types of malignant tumors. Traditional treatment methods mainly include radiotherapy， chemotherapy， and surgery， but the patients' prognosis is limited. In recent years， with the development in treatment methods， immunotherapy and targeted therapy are gradually recognized as the first-line treatment methods. In immunotherapy， nivolumab and pabolizumab have shown clear efficacy in patients with programmed death-ligand 1 positive， while other immunotherapies （such as tumor vaccine， engineered T cells， and non-specific immunomodulators） are still being tested or developed. In addition， targeted therapy has only shown comparatively large therapeutic potential in certain specific populations or in second-line treatment. For instance， tratuzumab has a clear curative effect on patients with positive human epidermal growth factor receptor 2， but has suboptimal efficacy in patients with amplification of other molecular targets. An in-depth discussion of the research progress of immunotherapy and targeted therapy in gastric cancer and EGJC will help to improve the prognosis of patients and provide a reference for accurate treatment of tumors.

Key words: Stomach neoplasms, Esophagogastric junction, Immunotherapy, Molecular targeted therapy

Wu Yang, Li Tian, Zhang Runbing, Shi Tingting, Gao Chun, Zheng Xiaofeng, Zhang Jiucong. Research progress in immunotherapy and targeted therapy for gastric cancer and esophagogastric junction cancer[J]. Journal of International Oncology, 2024, 51(9): 595-600.

References 44

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	Viale PH. The American cancer society's facts & figures: 2020 edition[J]. J Adv Pract Oncol, 2020, 11(2): 135-136. DOI: 10.6004/jadpro.2020.11.2.1.
[3]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358. DOI: 10.3760/cma.j.cn371439-20240318-00061.
[4]	Takimoto R, Kamigaki T, Ito H, et al. Safety evaluation of immune-cell therapy for malignant tumor in the cancer immune-cell therapy evaluation group(CITEG)[J]. Cytotherapy, 2023, 25(11): 1229-1235. DOI: 10.1016/j.jcyt.2023.06.007. pmid: 37486281
[5]	Yu Y, Ma X, Zhang Y, et al. Changes in expression of multiple checkpoint molecules and infiltration of tumor immune cells after neoadjuvant chemotherapy in gastric cancer[J]. J Cancer, 2019, 10(12): 2754-2763. DOI: 10.7150/jca.31755. pmid: 31258783
[6]	Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer[J]. N Engl J Med, 2021, 384(13): 1191-1203. DOI: 10.1056/NEJMoa2032125.
[7]	Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40. DOI: 10.1016/S0140-6736(21)00797-2. pmid: 34102137
[8]	Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2021, 398(10302): 759-771. DOI: 10.1016/S0140-6736(21)01234-4.
[9]	Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(10): 1571-1580. DOI: 10.1001/jamaoncol.2020.3370.
[10]	Quesada S, Samalin E, Thezenas S, et al. Perioperative FOLFOX in patients with locally advanced oesogastric adenocarcinoma[J]. Anticancer Res, 2022, 42(1): 185-193. DOI: 10.21873/anticanres.15472. pmid: 34969724
[11]	Liu R, Wang X, Ji Z, et al. Toripalimab combined with targeted therapy and chemotherapy achieves pathologic complete response in gastric carcinoma: a case report[J]. World J Clin Cases, 2022, 10(18): 6184-6191. DOI: 10.12998/wjcc.v10.i18.6184. pmid: 35949814
[12]	Depotte L, Palle J, Rasola C, et al. New developments and standard of care in the management of advanced gastric cancer[J]. Clin Res Hepatol Gastroenterol, 2024, 48(1): 102245. DOI: 10.1016/j.clinre.2023.102245.
[13]	杨柳, 王大榛, 赵璐, 等. 局部晚期胃癌围手术期免疫治疗研究进展[J]. 肿瘤学杂志, 2024, 30(4): 276-285. DOI: 10.11735/j.issn.1671-170X.2024.04.B003.
[14]	Wiedermann U, Garner-Spitzer E, Chao Y, et al. Clinical and immunologic responses to a B-cell epitope vaccine in patients with HER2/neu-overexpressing advanced gastric cancer-results from phase Ⅰb trial IMU.ACS.001[J]. Clin Cancer Res, 2021, 27(13): 3649-3660. DOI: 10.1158/1078-0432.CCR-20-3742. pmid: 33879458
[15]	Fucikova J, Hensler M, Kasikova L, et al. An autologous dendritic cell vaccine promotes anticancer immunity in patients with ovarian cancer with low mutational burden and cold tumors[J]. Clin Cancer Res, 2022, 28(14): 3053-3065. DOI: 10.1158/1078-0432.CCR-21-4413. pmid: 35536547
[16]	Zhang W, Lu X, Cui P, et al. Phase Ⅰ/Ⅱ clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer[J]. Cancer Immunol Immunother, 2019, 68(1): 121-130. DOI: 10.1007/s00262-018-2257-2. pmid: 30306202
[17]	Todo T, Ito H, Ino Y, et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial[J]. Nat Med, 2022, 28(8): 1630-1639. DOI: 10.1038/s41591-022-01897-x. pmid: 35864254
[18]	Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer[J]. Nature, 2023, 618(7963): 144-150. DOI: 10.1038/s41586-023-06063-y.
[19]	Tchernonog E, Moignet A, Anota A, et al. Health-related quality of life in patients with hematologic malignancies treated with chimeric antigen receptor T-cell therapy: review and current progress[J]. Haematologica, 2024, 109(8): 2401-2419. DOI: 10.3324/haematol.2022.282363.
[20]	文凤, 李秋. CAR-T在消化道实体瘤治疗中的研究进展与展望[J]. 延安大学学报(医学科学版), 2023, 21(4): 1-8. DOI: 10.19893/j.cnki.ydyxb.2023-0191.
[21]	Suh YS, Na D, Lee JS, et al. Comprehensive molecular characteri-zation of adenocarcinoma of the gastroesophageal junction between esophageal and gastric adenocarcinomas[J]. Ann Surg, 2022, 275(4): 706-717. DOI: 10.1097/SLA.0000000000004303.
[22]	Ter Veer E, van den Ende T, Creemers A, et al. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis[J]. Acta Oncol, 2018, 57(12): 1599-1604. DOI: 10.1080/0284186X.2018.1503421. pmid: 30264641
[23]	Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial[J]. Lancet, 2023, 402(10418): 2197-2208. DOI: 10.1016/S0140-6736(23)02033-0. pmid: 37871604
[24]	Rivera F, Izquierdo-Manuel M, García-Alfonso P, et al. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase Ⅱ trial[J]. Eur J Cancer, 2021, 145: 158-167. DOI: 10.1016/j.ejca.2020.12.005.
[25]	Tintelnot J, Stein A, Al-Batran SE, et al. Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase Ⅱ trial of the AIO study group(AIO STO 0321)[J]. Front Oncol, 2023, 13: 1272175. DOI: 10.3389/fonc.2023.1272175.
[26]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369. DOI: 10.3760/cma.j.cn371439-20231130-00063.
[27]	Shitara K. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: a plain language summary of the DESTINY-gastric01 study[J]. Future Oncol, 2024, 20(2): 59-70. DOI: 10.2217/fon-2023-0245.
[28]	邓莉莉, 段星宇, 李保中. HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757. DOI: 10.3760/cma.j.cn371439-20230911-00141.
[29]	Catenacci DVT, Kang YK, Park H, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial[J]. Lancet Oncol, 2020, 21(8): 1066-1076. DOI: 10.1016/S1470-2045(20)30326-0. pmid: 32653053
[30]	Augustin JE, Soussan P, Bass AJ. Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma[J]. Ann Oncol, 2022, 33(11): 1134-1148. DOI: 10.1016/j.annonc.2022.08.001. pmid: 35963482
[31]	Hanahan D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12(1): 31-46. DOI: 10.1158/2159-8290.CD-21-1059. pmid: 35022204
[32]	Xu RH, Zhang Y, Pan H, et al. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(12): 1015-1024. DOI: 10.1016/S2468-1253(21)00313-7.
[33]	Zhang TQ, Geng ZJ, Zuo MX, et al. Camrelizumab(a PD-1 inhibitor) plus apatinib(an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in barcelona clinic liver cancer stage C (TRIPLET): a phase Ⅱ study[J]. Signal Transduct Target Ther, 2023, 8(1): 413. DOI: 10.1038/s41392-023-01663-6.
[34]	Fuchs CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(3): 420-435. DOI: 10.1016/S1470-2045(18)30791-5. pmid: 30718072
[35]	Maron SB, Moya S, Morano F, et al. Epidermal growth factor receptor inhibition in epidermal growth factor receptor-amplified gastroesophageal cancer: retrospective global experience[J]. J Clin Oncol, 2022, 40(22): 2458-2467. DOI: 10.1200/JCO.21.02453.
[36]	Maron SB, Alpert L, Kwak HA, et al. Targeted therapies for targeted populations: anti-EGFR treatment for EGFR-Amplified gastroesophageal adenocarcinoma[J]. Cancer Discov, 2018, 8(6): 696-713. DOI: 10.1158/2159-8290.CD-17-1260.
[37]	Moosavi F, Giovannetti E, Peters GJ, et al. Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer[J]. Crit Rev Oncol Hematol, 2021, 160: 103234. DOI: 10.1016/j.critrevonc.2021.103234.
[38]	Kim HS, Kim JH, Jang HJ. Pathologic and prognostic impacts of FGFR2 amplification in gastric cancer: a meta-analysis and systemic review[J]. J Cancer, 2019, 10(11): 2560-2567. DOI: 10.7150/jca.29184.
[39]	Catenacci DVT, Rasco D, Lee J, et al. Phase Ⅰ escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma[J]. J Clin Oncol, 2020, 38(21): 2418-2426. DOI: 10.1200/JCO.19.01834. pmid: 32167861
[40]	Hashimoto I, Oshima T. Claudins and gastric cancer: an overview[J]. Cancers (Basel), 2022, 14(2): 290. DOI: 10.3390/cancers14020290.
[41]	Sahin U, Türeci Ö, Manikhas G, et al. FAST: a randomised phase Ⅱ study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma[J]. Ann Oncol, 2021, 32(5): 609-619. DOI: 10.1016/j.annonc.2021.02.005. pmid: 33610734
[42]	Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results[J]. Nat Med, 2022, 28(6): 1189-1198. DOI: 10.1038/s41591-022-01800-8. pmid: 35534566
[43]	Kim JH, Zang DY, Jang HJ, et al. A bayesian network meta-analysis on systemic therapy for previously treated gastric cancer[J]. Crit Rev Oncol Hematol, 2021, 167: 103505. DOI: 10.1016/j.critrevonc.2021.103505.
[44]	Lorenzen S, Knorrenschild JR, Pauligk C, et al. Phase Ⅲ rando-mized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)[J]. Int J Cancer, 2020, 147(9): 2493-2502. DOI: 10.1002/ijc.33025.